Skip to main content

Fiscal Wizard · Single-issue tearsheet

ANAB / Jun 21, 2026 Run #7388

ANAB

AnaptysBio, Inc.

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has collaborations agreement with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Composite verdict

A 82.6 / 100
Bullish setup · Reversal 12 drivers · 2 gates blocking
  • Vortex Signal
  • Elder Force Index
  • Pin Bar
Consider long call target Δ ~0.70 · ~35 DTE Bullish setup, Grade A → ITM call target

Industry rank 14th of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: range
Bull 100%Evidence: High · 24 signals0% Bear
Momentum Bullish 86Mean-reversion Neutral 58

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -82%
Asset value $1.28Earnings power value $22.15Price $57.51

Priced above its no-growth earnings power value ($22.15/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Above average

65.4 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
EPS Growth (YoY) 100
Margin of Safety 0
Revenue Growth (YoY) 100
Free Cash Flow Yield 2
Asset Turnover 100
P/B 25

Technicals Bullish

99.8 / 100

Bullish setup leads (Vortex Signal, Elder Force Index, Pin Bar); bears gated by guards. · 43 signals shown.

Strongest
Weakest
Vortex Signal 88
Elder Force Index 86
Rate of Change 86

Risk Gates

2 blocking 7 caution

2 guards active, 15 signals gated.

Realized Volatility Regime Blocking

High-vol regime mutes mean-reversion signals; low-vol regime mutes breakout signals.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Altman Z-Score Caution

Bottom-band Altman Z blocks bullish signals — distress risk.

Cash Ratio Caution

Visual cash-cushion flag — does not mute signals.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for ANAB.